These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 34112948)

  • 1. CEA, CA19-9, circulating DNA and circulating tumour cell kinetics in patients treated for metastatic colorectal cancer (mCRC).
    Sefrioui D; Beaussire L; Gillibert A; Blanchard F; Toure E; Bazille C; Perdrix A; Ziegler F; Gangloff A; Hassine M; Elie C; Bignon AL; Parzy A; Gomez P; Thill C; Clatot F; Sabourin JC; Frebourg T; Benichou J; Bouhier-Leporrier K; Gallais MP; Sarafan-Vasseur N; Michel P; Di Fiore F
    Br J Cancer; 2021 Aug; 125(5):725-733. PubMed ID: 34112948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinico-pathological correlation of serial measurement of circulating tumor cells in 24 metastatic colorectal cancer patients receiving chemotherapy reveals interpatient heterogeneity correlated with CEA levels but independent of KRAS and BRAF mutation.
    Das A; Kunkel M; Joudeh J; Dicker DT; Scicchitano A; Allen JE; Sarwani N; Yang Z; Kaifi J; Zhu J; Liao J; El-Deiry WS
    Cancer Biol Ther; 2015; 16(5):709-13. PubMed ID: 25806877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic monitoring of carcinoembryonic antigen, CA19-9 and inflammation-based indices in patients with advanced colorectal cancer undergoing chemotherapy.
    Manojlovic N; Savic G; Nikolic B; Rancic N
    World J Clin Cases; 2022 Jan; 10(3):899-918. PubMed ID: 35127905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gamma-glutamyl transpeptidase level is a novel adverse prognostic indicator in human metastatic colorectal cancer.
    He WZ; Guo GF; Yin CX; Jiang C; Wang F; Qiu HJ; Chen XX; Rong RM; Zhang B; Xia LP
    Colorectal Dis; 2013 Aug; 15(8):e443-52. PubMed ID: 23621885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating Cell Free DNA Integrity Index as a Biomarker for Response to Chemotherapy in Patients with Metastatic Colorectal Carcinoma.
    Eskander NS; Mansour L; Abdelaal A; Saad E; Mohamed D
    Asian Pac J Cancer Prev; 2022 Jan; 23(1):339-348. PubMed ID: 35092403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer.
    Aggarwal C; Meropol NJ; Punt CJ; Iannotti N; Saidman BH; Sabbath KD; Gabrail NY; Picus J; Morse MA; Mitchell E; Miller MC; Cohen SJ
    Ann Oncol; 2013 Feb; 24(2):420-428. PubMed ID: 23028040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients.
    Xu X; Yu Y; Shen M; Liu M; Wu S; Liang L; Huang F; Zhang C; Guo W; Liu T
    BMC Cancer; 2020 Oct; 20(1):1006. PubMed ID: 33066758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer.
    Spindler KL; Christensen IJ; Nielsen HJ; Jakobsen A; Brünner N
    Tumour Biol; 2015 Jun; 36(6):4301-8. PubMed ID: 25608838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients.
    Formica V; Massara MC; Portarena I; Fiaschetti V; Grenga I; Del Vecchio Blanco G; Sileri P; Tosetto L; Skoulidis F; Pallone F; Roselli M
    Cancer Biomark; 2009; 5(4):167-75. PubMed ID: 19729826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Highly Correlated Recurrence Prognosis in Patients with Metastatic Colorectal Cancer by Synergistic Consideration of Circulating Tumor Cells/Microemboli and Tumor Markers CEA/CA19-9.
    Chu HY; Yang CY; Yeh PH; Hsu CJ; Chang LW; Chan WJ; Lin CP; Lyu YY; Wu WC; Lee CW; Wu JK; Jiang JK; Tseng FG
    Cells; 2021 May; 10(5):. PubMed ID: 34068719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating tumour DNA at baseline for individualised prognostication in patients with chemotherapy-naïve metastatic colorectal cancer. An AGEO prospective study.
    Bachet JB; Laurent-Puig P; Meurisse A; Bouché O; Mas L; Taly V; Cohen R; Gornet JM; Artru P; Louafi S; Thirot-Bidault A; Baumgaertner I; Coriat R; Tougeron D; Lecomte T; Mary F; Aparicio T; Marthey L; Blons H; Vernerey D; Taieb J
    Eur J Cancer; 2023 Aug; 189():112934. PubMed ID: 37390800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between circulating tumor DNA and carcinoembryonic antigen levels in patients with metastatic colorectal cancer.
    Osumi H; Shinozaki E; Ooki A; Shimozaki K; Kamiimabeppu D; Nakayama I; Wakatsuki T; Ogura M; Takahari D; Chin K; Yamaguchi K
    Cancer Med; 2021 Dec; 10(24):8820-8828. PubMed ID: 34821068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers for the early detection of relapses in metastatic colorectal cancers.
    Chereches G; Barbos O; Buiga R; Balacescu O; Iancu D; Todor N; Balacescu L; Miron N; Bejinariu N; Ciuleanu TE
    J BUON; 2017; 22(3):658-666. PubMed ID: 28730771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Threshold Change in CEA as a Predictor of Non-Progression to First-Line Systemic Therapy in Metastatic Colorectal Cancer Patients With Elevated CEA.
    Gulhati P; Yin J; Pederson L; Schmoll HJ; Hoff P; Douillard JY; Hecht JR; Tournigand C; Tebbut N; Chibaudel B; Gramont A; Shi Q; Overman MJ
    J Natl Cancer Inst; 2020 Nov; 112(11):1127-1136. PubMed ID: 32191317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring levels of circulating cell-free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment.
    Pastor B; André T; Henriques J; Trouilloud I; Tournigand C; Jary M; Mazard T; Louvet C; Azan S; Bauer A; Roch B; Sanchez C; Vernerey D; Thierry AR; Adenis A
    Mol Oncol; 2021 Sep; 15(9):2401-2411. PubMed ID: 33934494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined detection of preoperative serum CEA, CA19-9 and CA242 improve prognostic prediction of surgically treated colorectal cancer patients.
    Wang J; Wang X; Yu F; Chen J; Zhao S; Zhang D; Yu Y; Liu X; Tang H; Peng Z
    Int J Clin Exp Pathol; 2015; 8(11):14853-63. PubMed ID: 26823815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of changes in systemic inflammatory markers and carcinoembryonic antigen levels in predicting metastatic colorectal cancer prognosis and chemotherapy response.
    Kim IH; Lee JE; Yang JH; Jeong JW; Ro S; Lee MA
    Asia Pac J Clin Oncol; 2018 Jun; 14(3):239-246. PubMed ID: 29044941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer.
    Hamfjord J; Guren TK; Glimelius B; Sorbye H; Pfeiffer P; Dajani O; Lingjaerde OC; Tveit KM; Pallisgaard N; Spindler KG; Kure EH
    Int J Cancer; 2021 Sep; 149(6):1385-1397. PubMed ID: 33961700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies.
    Moretto R; Rossini D; Conca V; Lonardi S; Rasola C; Antoniotti C; Santini D; Marmorino F; Tomasello G; Borelli B; Caponnetto S; Zucchelli G; Zaniboni A; Ambrosini M; Buonadonna A; Fanchini L; Cupini S; Masi G; Falcone A; Cremolini C
    Br J Cancer; 2021 Sep; 125(6):839-845. PubMed ID: 34253871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between early dynamics in circulating tumour DNA and outcome from FOLFIRI treatment in metastatic colorectal cancer.
    Lyskjær I; Kronborg CS; Rasmussen MH; Sørensen BS; Demuth C; Rosenkilde M; Johansen AFB; Knudsen M; Vang S; Krag SRP; Spindler KG; Andersen CL
    Sci Rep; 2019 Aug; 9(1):11542. PubMed ID: 31395942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.